NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company will present a corporate update via live webcast immediately following the business portion of its 2016
NORCROSS, Ga., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has recently completed a private placement of its common stock, raising $3,000,000 in new funding. In a separate transaction, the Company also closed an additional sal...
The Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com NORCROSS, Ga., Jan. 30, 2017 /CNW/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Trabe...
NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated sufficient financing to cover currently planned expenditures through 2017 and it remains on track to present top line data from its NASH-CX Phase 2 clinica...
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NORCROSS, Ga., Feb. 6, 2017 /CNW/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the February 2nd presenta...
NORCROSS, Ga., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and the Providence Cancer Center today announced the presentation of preclinical and early clinical data from two investigator-initiated Phase 1 clinical trials of GR-MD-02 used in combina...
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will present at BIO CEO & Investor Conference on Monday, February 13, 2017 at 3:00 p.m. Eastern time. The...
Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24-week treatment period NORCROSS, Ga., March 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced results from an explorat...
NORCROSS, Ga., March 09, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will present at the 29th Annual ROTH Conference on Wednesday, March 15, 2017 at 11:30 a.m. Pacific Time....
NORCROSS, Ga., March 14, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced preliminary results for severe and refractory atopic dermatitis from a small, open label, investigator-initiated study with GR-MD-02 that has enrolled 3 patients. There we...
